Patients with 'late presentation' (LP) of chronic hepatitis C infection (HCV) have already developed advanced liver disease before receiving direct-acting antiviral (DAA) treatment. Even after successful treatment, the risk of morbidity and premature death remains elevated, leading to an unnecessary disease burden. This study aimed to assess the prevalence of LP within the prospective observational Swiss Hepatitis C Cohort (SCCS) and evaluate risk factors as determinants of LP.

中文翻译：

---

丙型肝炎治疗的晚期表现：瑞士丙型肝炎队列中的患病率和危险因素。

慢性丙型肝炎感染（HCV）“晚期表现”（LP）患者在接受直接抗病毒（DAA）治疗之前就已经发展为晚期肝病。即使治疗成功，发病和过早死亡的风险仍然很高，导致不必要的疾病负担。本研究旨在评估瑞士丙型肝炎前瞻性队列 (SCCS) 中 LP 的患病率，并评估作为 LP 决定因素的危险因素。